Pfizer and Roivant launch autoimmune specialist Priovant
The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer […]
The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer […]
Shots: Roivant signs a SPAC merger with MAAC for ~7.3B including $411M in cash in the MAAC trust account and $200M in PIPE stock at […]
Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata Published: Mar 5, 2021 | Tags: Eli Lilly […]
Shots: Roivant to acquire Silicon for $450M in Roivant’s equity with additional potential regulatory and commercial milestones. The acquisition will strengthen Roivant’s AI capabilities for […]
The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common […]
Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing […]
Copyright © 2024 | WordPress Theme by MH Themes